News / Taiwan / economic_daily
PharmaEssentia Expands into Australia with New Drug Application Prep
Health Technology · Pharmaceuticals: Major · economic_daily · 2026-09-23
6446
PharmaEssentia is establishing an Australian base to initiate regulatory approval processes for its flagship drug, Ropeg, in the local market.
What Happened
Australian Expansion: PharmaEssentia will establish a presence at the Centre for Eye Research Australia (CERA) on October 1st. This move marks the official start of preparations for regulatory approval of its drug, Ropeg, for the treatment of polycythemia vera (PV) and essential thrombocythemia (ET) in Australia.
Leveraging Local Expertise: By joining CERA, the company aims to integrate into the Melbourne biomedical research ecosystem. Access to Australia's robust clinical trial infrastructure and academic partnerships will accelerate the company's local development and regulatory capabilities.
Global Direct Strategy: The company continues to execute its global direct-sales strategy, having already established subsidiaries in the U.S., Japan, South Korea, China, and Singapore. The recent acquisition of FORUS Therapeutics in Canada further underscores its commitment to strengthening its North American footprint.
Pipeline Development: Beyond its focus on myeloproliferative neoplasms (MPN), PharmaEssentia is advancing a diverse pipeline of drug candidates. The new Australian team will prioritize the Ropeg regulatory filing while supporting ongoing clinical trials for other pipeline assets in the region.
Read original
More in Health Technology
Health Technology · economic_daily · 2026-09-23
Adimmune's subsidiary, Enimmune, has signed an exclusive distribution deal with Thailand's Biogenetech to supply EV71 vaccines to the Thai market.
6564
Health Technology · economic_daily · 2026-09-23
OBI Pharma's stock staged a strong recovery today, climbing from an early low to hit the daily limit up, sparking speculation about potential positive developments.
Health Technology · economic_daily · 2026-09-23
Taiwan's health ministry plans to cut new drug approval times to 100 days, sparking a rally in local biotech stocks like TLC-KY amid improved regulatory outlooks.
4174, 6610, 6696, 6838, 7924
Latest in Taiwan
Electronic Technology · economic_daily · 2026-09-23
Zhen Ding Tech has successfully priced an $800 million overseas convertible bond, drawing over seven times the demand from global institutional investors.
4958
Electronic Technology · economic_daily · 2026-09-23
Taiwan's stock market reached a historic milestone, closing above 48,000 points with a market cap of $5.3 trillion, as analysts eye the 50,000-point mark.
2330, 2368, 2404, 2454, 3443, 3653, 6488, 6805
Finance · economic_daily · 2026-09-23
Taiwan's central bank reported a record high in securities deposits for August, fueled by record-breaking corporate dividend payouts and resilient retail participation.
Electronic Technology · economic_daily · 2026-09-23
Driven by robust AI demand and steady ETF inflows, analysts are bullish on Taiwan stocks, with some projecting the index to hit 55,000 by year-end.